Kiromic Biopharma Inc (KRBP)

NASDAQ
0.202
-0.018(-8.11%)
  • Volume:
    5,193,115
  • Day's Range:
    0.195 - 0.217
  • 52 wk Range:
    0.150 - 1.000
Unusual trading volume

Kiromic has doubled (or more) its daily average of shares traded over the last 3 months. High volumes usually indicate new trends and larger share price movements.

KRBP Overview

Prev. Close
0.22
Day's Range
0.195-0.217
Revenue
-
Open
0.217
52 wk Range
0.15-1
EPS
-2.47
Volume
5,193,115
Market Cap
3.63M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,143,633
P/E Ratio
-0.08
Beta
0.049
1-Year Change
-76.88%
Shares Outstanding
18,246,718
Next Earnings Date
28 Mar 2023
What is your sentiment on Kiromic?
or
Vote to see community's results!

Kiromic Biopharma Inc News

Kiromic Biopharma Inc Analysis

Kiromic Biopharma Inc Company Profile

Kiromic Biopharma Inc Company Profile

Kiromic BioPharma, Inc. is an artificial intelligence (AI) driven, end-to-end allogenic cell therapy company. The Company is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellStrong SellStrong SellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell